PMID- 28979339
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240327
IS  - 1735-0328 (Print)
IS  - 1726-6890 (Electronic)
IS  - 1726-6882 (Linking)
VI  - 16
IP  - 2
DP  - 2017 Spring
TI  - New Product Development in the Pharmaceutical Industry: Evidence from a generic 
      market.
PG  - 834-846
AB  - In today's competitive world, there are several strategies to deal with the fast 
      changing environment, among which New product development (NPD) is a common 
      strategy. However, almost half of the resources that companies devote to NPD are 
      spent on products that may fail. This issue is particularly highlighted in the 
      pharmaceutical industry mainly because of a long development-time, low success 
      rate, high capital requirement, and market uncertainty. This study identifies 
      critical success factors of NPD based on the relevant literatures and expert 
      opinions in Iranian pharmaceutical industry, then prioritizes them using the 
      methodology of multiple criteria decision making (MCDM) through analyzing 50 
      filled questionnaires structured based on the AHP (Analytical Hierarchy Process) 
      approach. Although the NPD success factors seem the same in both generic and 
      bio-generic pharmaceutical industries, the underlying factors and related 
      sub-factors show the different importance in these two industries. However, this 
      study reveal that, the company capabilities is the most important factor 
      affecting new product development success in both pharmaceutical generic and 
      bio-generic industry. The results of this study contribute to create baseline 
      information for pharmaceutical industry especially Iranian pharmaceutical 
      companies to be more effective in budget allocation on improving NPD success 
      factors so that they can boost the success rate of NPD more effectively.
FAU - Yousefi, Nazila
AU  - Yousefi N
AD  - Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran.
AD  - Students' research committee, school of pharmacy, Shahid Beheshti University of 
      Medical Sciences, Tehran, Iran.
FAU - Mehralian, Gholamhossein
AU  - Mehralian G
AD  - Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Rasekh, Hamid Reza
AU  - Rasekh HR
AD  - Department of Pharmacoeconomics and Pharma Management, School of Pharmacy, Shahid 
      Beheshti University of Medical Sciences, Tehran, Iran.
FAU - Yousefi, Mina
AU  - Yousefi M
AD  - Department of technology management, School of management and accounting, Azad 
      University, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Iran J Pharm Res
JT  - Iranian journal of pharmaceutical research : IJPR
JID - 101208407
PMC - PMC5603895
OTO - NOTNLM
OT  - Analytical Hierarchy Process
OT  - Iran
OT  - New product development
OT  - Pharmaceutical industry
EDAT- 2017/10/06 06:00
MHDA- 2017/10/06 06:01
PMCR- 2017/03/01
CRDT- 2017/10/06 06:00
PHST- 2017/10/06 06:00 [entrez]
PHST- 2017/10/06 06:00 [pubmed]
PHST- 2017/10/06 06:01 [medline]
PHST- 2017/03/01 00:00 [pmc-release]
AID - ijpr-16-834 [pii]
PST - ppublish
SO  - Iran J Pharm Res. 2017 Spring;16(2):834-846.